Scarica l'app Stockscreener
25.00
2.29%
0.56
Precedente Chiudi:
$24.44
Aprire:
$24.61
Volume 24 ore:
638.47K
Relative Volume:
0.78
Capitalizzazione di mercato:
$2.82B
Reddito:
$14.09M
Utile/perdita netta:
$-176.94M
Rapporto P/E:
-11.63
EPS:
-2.15
Flusso di cassa netto:
$-141.24M
1 W Prestazione:
-0.28%
1M Prestazione:
+9.03%
6M Prestazione:
+34.63%
1 anno Prestazione:
+51.24%
Intervallo 1D:
$24.35
$25.65
Intervallo di 1 settimana:
$23.68
$25.90
Portata 52W:
$14.06
$27.29
Newamsterdam Pharma Company Nv Stock (NAMS) Company Profile
Nome
Newamsterdam Pharma Company Nv
Settore
Industria
Telefono
35 206 2971
Indirizzo
GOOIMEER 2-35, NARRDEN
Confronta NAMS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NAMS
Newamsterdam Pharma Company Nv
|
25.00 | 2.86B | 14.09M | -176.94M | -141.24M | -2.15 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Newamsterdam Pharma Company Nv Stock (NAMS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-17 | Iniziato | Goldman | Neutral |
| 2025-06-17 | Iniziato | Citigroup | Buy |
| 2025-06-10 | Iniziato | Stifel | Buy |
| 2025-06-04 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-12-30 | Iniziato | H.C. Wainwright | Buy |
| 2024-05-15 | Iniziato | TD Cowen | Buy |
| 2024-03-14 | Iniziato | Scotiabank | Sector Outperform |
| 2024-01-18 | Iniziato | Guggenheim | Buy |
| 2024-01-16 | Iniziato | Piper Sandler | Overweight |
| 2023-10-30 | Iniziato | RBC Capital Mkts | Outperform |
Mostra tutto
Newamsterdam Pharma Company Nv Borsa (NAMS) Ultime notizie
Published on: 2025-08-20 15:56:49 - beatles.ru
NewAmsterdam announces acceptance of MAA for review by EMA for obicetrapib - MSN
NewAmsterdam Pharma Company N.V. (NAMS) Reports Q2 Loss, Tops Revenue Estimates - MSN
Rainbows and Unicorns: NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Analysts Just Became A Lot More Optimistic - simplywall.st
NewAmsterdam Announces Acceptance of Marketing Authorization Applications f - TradeVenue
Nov Inc. shares rise 1.36% intraday after NewAmsterdam Pharma Company N.V. announced regulatory submissions for obicetrapib. - AInvest
NewAmsterdam Announces Acceptance of Marketing - GlobeNewswire
40% LDL Reduction: NewAmsterdam's Novel Oral Cholesterol Drug Could Help Millions Missing Treatment Goals - Stock Titan
Chart overlay techniques for tracking NewAmsterdam Pharma Company N.V.2025 Year in Review & Reliable Volume Spike Trade Alerts - Newser
How to integrate NewAmsterdam Pharma Company N.V. Equity Warrant into portfolio analysis toolsGap Up & Smart Allocation Stock Tips - Newser
Is this a good reentry point in NewAmsterdam Pharma Company N.V. Equity Warrant2025 Performance Recap & Free Technical Confirmation Trade Alerts - Newser
News impact scoring models applied to NewAmsterdam Pharma Company N.V2025 Major Catalysts & Verified High Yield Trade Plans - Newser
Using Python tools to backtest NewAmsterdam Pharma Company N.V. strategies2025 Market Trends & Community Consensus Stock Picks - Newser
News impact scoring models applied to NewAmsterdam Pharma Company N.V.Weekly Trade Review & Daily Oversold Stock Bounce Ideas - Newser
Visual analytics tools that track NewAmsterdam Pharma Company N.V. performancePortfolio Update Summary & Advanced Swing Trade Entry Plans - Newser
Can NewAmsterdam Pharma Company N.V. recover in the next quarterEarnings Risk Report & Risk Managed Investment Entry Signals - Newser
Heatmap analysis for NewAmsterdam Pharma Company N.V. Equity Warrant and competitorsIPO Watch & Risk Controlled Swing Alerts - Newser
Price action breakdown for NewAmsterdam Pharma Company N.V.Wall Street Watch & Intraday High Probability Alerts - Newser
Can NewAmsterdam Pharma Company N.V. Equity Warrant recover in the next quarterEarnings Growth Summary & Weekly Chart Analysis and Guides - Newser
Will NewAmsterdam Pharma Company N.V. Equity Warrant benefit from macro trends - Newser
Does NewAmsterdam Pharma Company N.V. Equity Warrant fit your quant trading model2025 Price Action Summary & Risk Adjusted Buy/Sell Alerts - Newser
How to use Fibonacci retracement on NewAmsterdam Pharma Company N.V. Equity WarrantPortfolio Return Report & Long-Term Safe Investment Ideas - Newser
NewAmsterdam Pharma Company N.V. Equity Warrant’s volatility index tracking explainedEarnings Risk Report & Consistent Profit Focused Trading Strategies - Newser
Applying chart zones and confluence areas to NewAmsterdam Pharma Company N.V.2025 Sector Review & High Yield Stock Recommendations - Newser
Is NewAmsterdam Pharma Company N.V. trending in predictive chart models2025 Investor Takeaways & Daily Stock Trend Watchlist - Newser
Can momentum traders help lift NewAmsterdam Pharma Company N.V.2025 Price Action Summary & AI Driven Price Predictions - Newser
NewAmsterdam Pharma Signs Supply Agreement with Menarini - MSN
Short interest data insights for NewAmsterdam Pharma Company N.V.July 2025 Recap & Free Fast Gain Swing Trade Alerts - Newser
How moving averages guide NewAmsterdam Pharma Company N.V. trading2025 Biggest Moves & Free High Accuracy Swing Entry Alerts - Newser
How to build a dashboard for NewAmsterdam Pharma Company N.V. Equity Warrant stockPortfolio Growth Summary & Free Risk Controlled Daily Trade Plans - Newser
Can technical indicators confirm NewAmsterdam Pharma Company N.V.’s reversalJuly 2025 Spike Watch & Reliable Price Breakout Alerts - Newser
NewAmsterdam Pharma Company N.V. Equity Warrant’s Price Action Aligns with Quant SignalsJuly 2025 Spike Watch & Fast Gain Stock Tips - sundaytimes.kr
What makes NewAmsterdam Pharma Company N.V. stock price move sharply2025 EndofYear Setup & Safe Entry Zone Tips - Newser
Published on: 2025-08-15 19:06:53 - sundaytimes.kr
How to interpret RSI for NewAmsterdam Pharma Company N.V. Equity Warrant stock2025 Stock Rankings & Community Trade Idea Sharing Platform - Newser
Live market analysis of NewAmsterdam Pharma Company N.V.July 2025 Trade Ideas & AI Enhanced Execution Alerts - Newser
NewAmsterdam Pharma Company N.V. Announces Resignation of Michael Davidson as Chief Executive Officer, Effective August 11, 2025 - MarketScreener
NewAmsterdam Pharma Director Topper James N Buys 471 Shares at $23.98/Share. - AInvest
New Amsterdam Pharma director Topper buys $11k in shares By Investing.com - Investing.com South Africa
New Amsterdam Pharma director Topper buys $11k in shares - Investing.com
Published on: 2025-08-13 00:48:28 - 선데이타임즈
Analysts Just Made A Massive Upgrade To Their NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Forecasts - 富途牛牛
Piper Sandler reiterates Overweight rating on NewAmsterdam Pharma stock By Investing.com - Investing.com Nigeria
Piper Sandler reiterates Overweight rating on NewAmsterdam Pharma stock - Investing.com India
William Blair Brokers Increase Earnings Estimates for NAMS - Defense World
Leerink Partnrs Issues Optimistic Outlook for NAMS Earnings - Defense World
Bullish: Analysts Just Made A Meaningful Upgrade To Their NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Forecasts - Yahoo Finance
Analysts Are Upgrading NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) After Its Latest Results - Yahoo Finance
Comparing NewAmsterdam Pharma Company N.V. Equity Warrant in custom built stock radarsFree Trade Setups With Clear Risk Limits - Newser
Visualizing NewAmsterdam Pharma Company N.V. Equity Warrant stock with heatmapsWeekly Price Target Forecast and Alerts - Newser
Technical analysis overview for NewAmsterdam Pharma Company N.V. stockFree AI Driven Buy Alert Trade Blueprint - Newser
Newamsterdam Pharma Company Nv Azioni (NAMS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Newamsterdam Pharma Company Nv Azioni (NAMS) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Kling Douglas F | Chief Operating Officer |
Jul 16 '25 |
Option Exercise |
10.90 |
51,043 |
556,369 |
95,043 |
| Kling Douglas F | Chief Operating Officer |
Jul 15 '25 |
Option Exercise |
10.90 |
47,569 |
518,502 |
91,569 |
| Kling Douglas F | Chief Operating Officer |
Jul 16 '25 |
Sale |
21.10 |
51,043 |
1,077,007 |
44,000 |
| Kling Douglas F | Chief Operating Officer |
Jul 15 '25 |
Sale |
21.44 |
47,569 |
1,019,648 |
44,000 |
0.94%
1.72%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):